CALC (CalciMedica) Current Accrued Expense: $1.37 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CALC CalciMedica Inc CALC
30 GF Score
Price $0.67
! 2 Warning Signs
View Full Analysis

What is CalciMedica Current Accrued Expense?

CalciMedica CALC +3.17% 30 Current Accrued Expense is $1.37 Mil as of Jun. 2026. GuruFocus rates CALC with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

CalciMedica's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1.37 Mil.

CalciMedica's quarterly Current Accrued Expense declined from Dec. 2025 ($1.37 Mil) to Mar. 2026 ($1.07 Mil) but then increased from Mar. 2026 ($1.07 Mil) to Jun. 2026 ($1.37 Mil).

CalciMedica's annual Current Accrued Expense declined from Dec. 2023 ($2.52 Mil) to Dec. 2024 ($1.69 Mil) and declined from Dec. 2024 ($1.69 Mil) to Dec. 2025 ($1.37 Mil).

CalciMedica Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for CalciMedica's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CalciMedica Current Accrued Expense Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 2.58 1.71 2.52 1.69 1.37

CalciMedica Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 2.55 1.37 1.07 1.37
CALC
30GF Score
CalciMedica Inc CALC
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CalciMedica Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.37 Mil mean?
CalciMedica (CALC) has a Current Accrued Expense of $1.37 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on CalciMedica and its competitors.
Is CalciMedica's Current Accrued Expense too high?
CalciMedica's current Current Accrued Expense is $1.37 Mil. Overall, CalciMedica has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CalciMedica's Current Accrued Expense compare to INTS and PHIO?
CalciMedica's Current Accrued Expense of $1.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on CalciMedica and its competitors. CalciMedica's current Current Accrued Expense is $1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CalciMedica stock overvalued right now?
CalciMedica (CALC) has a current Current Accrued Expense of $1.37 Mil. The current Current Accrued Expense is $1.37 Mil. CalciMedica's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For CalciMedica (CALC), the current Current Accrued Expense is $1.37 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CalciMedica Business Description

Address 505 Coast Boulevard South, Suite 307, La Jolla, CA, USA, 92037
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
30GF Score

Get the complete analysis for CALC

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price